LOGIN  |  REGISTER

List of Diagnostics & Research Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 427.50
-9.29 -2.13
3.00M
382.50M
US$ 163.520B
US$ 186.83
-3.83 -2.01
3.58M
722.28M
US$ 134.940B
US$ 411.49
9.11 2.26
952,396
81.88M
US$ 33.690B
US$ 102.48
-33.62 -24.70
1.72M
285.60M
US$ 29.270B
US$ 68.57
-0.16 -0.23
3.59M
390.60M
US$ 26.780B
US$ 143.91
-4.53 -3.05
3.26M
181.50M
US$ 26.120B
US$ 1.00
-11.69 -1.15
209,770
21.10M
US$ 21.200B
US$ 148.08
-2.09 -1.39
578,493
132.02M
US$ 19.550B
US$ 321.01
-0.09 -0.03
421,182
59.38M
US$ 19.060B
US$ 163.80
-0.67 -0.41
1.48M
111.62M
US$ 18.280B
US$ 217.12
-3.45 -1.56
750,058
83.64M
US$ 18.160B
US$ 139.32
-4.22 -2.94
1.75M
82.56M
US$ 11.500B
US$ 71.20
-2.33 -3.17
2.60M
158.60M
US$ 11.290B
US$ 91.82
-1.93 -2.06
1.32M
121.70M
US$ 11.170B
US$ 296.28
-0.22 -0.07
696,457
31.08M
US$ 9.210B
US$ 40.71
-0.73 -1.76
1.71M
222.26M
US$ 9.050B
US$ 41.58
-0.68 -1.61
3.12M
185.08M
US$ 7.700B
US$ 101.32
0.80 0.80
408,155
69.53M
US$ 7.040B
US$ 40.45
-0.41 -1.00
4.55M
152.40M
US$ 6.160B
US$ 44.97
-0.21 -0.46
1.80M
123.56M
US$ 5.560B
US$ 106.05
1.80 1.73
1.61M
51.14M
US$ 5.420B
US$ 49.78
-0.74 -1.46
691,130
74.03M
US$ 3.690B
US$ 10.48
-0.01 -0.10
834,189
283.24M
US$ 2.970B
US$ 36.80
-1.65 -4.29
726,130
59.58M
US$ 2.190B
US$ 25.17
-0.10 -0.40
910,990
67.26M
US$ 1.690B
US$ 9.55
-0.01 -0.10
1.34M
128.36M
US$ 1.230B
US$ 1.43
0.01 0.70
1.82M
672.80M
US$ 962.100M
US$ 4.39
-0.21 -4.57
12.32M
216.94M
US$ 952.370M
US$ 17.62
-0.60 -3.29
512,969
53.63M
US$ 944.960M
US$ 7.64
-0.27 -3.41
1.57M
91.04M
US$ 695.550M
US$ 21.51
0.25 1.18
445,939
28.01M
US$ 602.500M
US$ 4.05
0.00 0.00
86,544
139.82M
US$ 566.270M
US$ 17.86
-0.46 -2.51
266,908
30.59M
US$ 546.340M
US$ 1.16
0.03 2.65
689,162
372.26M
US$ 431.820M
US$ 27.57
-0.57 -2.03
45,985
14.29M
US$ 393.980M
US$ 1.17
-0.03 -2.50
3.97M
294.32M
US$ 344.350M
US$ 10.54
0.01 0.09
80,500
23.48M
US$ 247.480M
C$ 0.82
0.00 0.00
66,736
282.82M
C$ 231.910M
US$ 3.76
-0.01 -0.27
301,132
55.65M
US$ 209.240M
US$ 1.15
-0.01 -0.86
1.61M
138.40M
US$ 159.160M
US$ 3.40
0.05 1.49
85,122
32.80M
US$ 111.520M
US$ 0.55
-0.0046 -0.83
374,091
145.47M
US$ 79.860M
US$ 1.60
0.06 3.56
15,252
49.50M
US$ 79.200M
US$ 4.49
0.02 0.45
37,708
17.64M
US$ 79.200M
US$ 1.64
-0.01 -0.61
523,432
32.02M
US$ 52.510M
C$ 0.45
0.01 2.30
23,100
113.40M
C$ 50.460M
US$ 0.83
0.03 3.75
464,705
55.19M
US$ 45.810M
US$ 0.47
-0.03 -5.80
168,301
95.97M
US$ 45.200M
US$ 1.63
-0.04 -2.11
52,763
26.67M
US$ 43.340M
US$ 4.01
0.41 11.39
3,316
10.64M
US$ 42.670M
US$ 3.83
1.93 101.58
2,137
10.07M
US$ 38.570M
US$ 0.75
0.05 7.14
423,466
38.39M
US$ 28.790M
US$ 1.72
0.06 3.61
168,292
15.37M
US$ 26.440M
US$ 2.80
-0.10 -3.45
12,063
8.53M
US$ 23.880M
C$ 0.25
0.00 0.00
10,000
90.89M
C$ 22.720M
C$ 0.30
0.00 0.00
0
59.60M
C$ 17.880M
US$ 0.32
-0.06 -16.67
4.07M
52.24M
US$ 16.610M
US$ 2.67
0.00 0.00
0
5.89M
US$ 15.730M
US$ 0.55
0.01 1.85
38,308
27.52M
US$ 15.140M
US$ 0.55
-0.01 -1.81
5,296
25.04M
US$ 13.750M
US$ 0.61
0.00 0.00
0
19.01M
US$ 11.520M
US$ 0.35
0.01 2.97
23,203
31.93M
US$ 11.080M
C$ 0.09
0.00 0.00
0
100.02M
C$ 9.000M
US$ 5.88
0.37 6.72
5,076
1.48M
US$ 8.700M
US$ 0.52
0.05 9.67
485,497
15.58M
US$ 8.020M
US$ 3.22
0.02 0.62
38,993
2.22M
US$ 7.150M
C$ 0.04
0.00 0.00
0
122.72M
C$ 4.910M
C$ 0.05
0.00 0.00
0
96.48M
C$ 4.820M
C$ 0.05
0.00 0.00
0
101.29M
C$ 4.560M
US$ 0.67
-0.0067 -1.00
4,061
5.85M
US$ 3.900M
US$ 0.78
0.00 0.00
0
4.85M
US$ 3.780M
US$ 0.11
-0.0024 -2.21
23,992
21.04M
US$ 2.230M
US$ 3.67
0.32 9.55
2.09M
536,908
US$ 1.970M
US$ 0.08
0.00 0.00
0
16.67M
US$ 1.370M
US$ 1.24
-0.09 -6.44
35,971
962,637
US$ 1.190M
US$ 0.00
0.00 0.00
0
6.39M
US$ -

Latest News From Diagnostics & Research Stocks


Tempus AI Unveils Advisory Board Featuring Leading Physicians From Across the U.S.

CHICAGO / Apr 18, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of the Tempus Advisory Board. The Tempus Advisory Board is a vital resource for the company in maintaining high standards and ensuring that the strategy and offerings continue to be grounded in expert knowledge from outside the organization. This group of engaged medical professionals... Read more


bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

Process optimization enhances data acquisition and processing speed, lowers reagent costs, and maintains test performance for early lung cancer detection. SAN ANTONIO / Apr 17, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer, today announced implementation of key efficiency measures for its flagship product, CyPath® Lung,... Read more


DarioHealth Collaborates with Leading National Benefit Plan Administrator to Offer Cardiometabolic Solution including a GLP-1 Support Program to Employers

Strategic partnership expands Dario's employer footprint and has already started contributing to recurring revenues in Q1 of 2025 NEW YORK, April 17, 2025 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a new strategic partnership with a leading benefit administrator to deliver its comprehensive cardiometabolic solution including a GLP-1 support program and full AI-driven digital... Read more


Agilent Technologies Receives European IVDR Certification for Companion Diagnostic Assay in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

European certification for PD-L1 IHC 22C3 pharmDx to help gastric or GEJ adenocarcinoma patients for KEYTRUDA® therapy SANTA CLARA, Calif. / Apr 17, 2025 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the use as a Companion Diagnostic (CDx) to aid in the identification of gastric or gastroesophageal Junction (GEJ) adenocarcinoma patients who may be eligible... Read more


Spectral Medical Completes Tigris Trial Enrollment

157 patients enrolled Topline results expected to be released in August 2025 Company to host Corporate Update Call on May 15, 2025 TORONTO, April 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the completion of full enrollment in the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use... Read more


RadNet to Acquire iCAD to Accelerate AI-Powered Early Detection and Diagnosis of Breast Cancer

The acquisition will unite complementary leading AI-powered cancer detection and workflow solutions focused on improving the accuracy and early detection of breast cancer The transaction is expected to add to RadNet’s wholly owned subsidiary, DeepHealth, an installed base of over 1,500 healthcare provider locations across over 50 countries With iCAD’s seasoned commercial and engineering team anticipated to join DeepHealth, the combination is expected to accelerate... Read more


Illumina and Tempus AI partner to drive the future of precision medicine through genomic AI innovation

Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease SAN DIEGO and CHICAGO, April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation.... Read more


QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation

Three new innovative instrument launches expand reach into further lab segments and sample preparation customers as QIAGEN strengthens market-leading position QIAsymphony Connect set to start phased launch in 2025, first customer sessions being held to highlight enhanced capabilities for oncology and genomics workflows QIAsprint and QIAmini on track for 2026 launches, expanding options for high- and low-throughput lab demands VENLO, Netherlands / Apr 15, 2025 / Business... Read more


Exact Sciences: JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups

Comprehensive review confirms that the Oncotype DX Breast Recurrence Score® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity MADISON, Wis. / Apr 14, 2025 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the publication of a comprehensive review in JAMA Oncology that strengthens the evidence supporting the Oncotype DX... Read more


DexCom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System

Dexcom G7 15 Day* is now cleared in the US for people age 18 years and above with diabetes. Now the longest lasting*,†,1 and most accurate1 CGM system, Dexcom G7 15 Day gives users the knowledge to better control diabetes. For people between the ages 2 to 18, Dexcom G7 remains the most accurate2 continuous glucose monitoring system. SAN DIEGO / Apr 10, 2025 / Business Wire / DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the... Read more


Telo Genomics Announces Acceptance of its MRD Validation Data in Multiple Myeloma for ASCO 2025

Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, today announced that the American Society of Clinical Oncology (ASCO) has accepted Telo Genomics' abstract submission regarding a concordance analysis between blood and marrow samples, using the TeloView® Minimal Residual... Read more


PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million

Implements Plan to Reduce Annualized Operating Expense Run Rate by $45 Million to $50 Million Q1 2025 Earnings Conference Call Scheduled for May 8, 2025 MENLO PARK, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2025. Preliminary First Quarter Results   Preliminary Q1 2025 Q1 2024 Revenue $36.9 million $38.8 million Instrument... Read more


Quest Diagnostics Launches New AD-Detect™ Blood Test to Aid in Confirming Alzheimer's Disease

In an oral presentation at the 2025 AAN Annual Meeting, Quest scientists presented data suggesting the test can accurately assess Alzheimer's disease pathology with greater than 90% sensitivity and specificity SECAUCUS, N.J., April 9, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced the launch of a new laboratory blood test designed to help physicians... Read more


Top U.S. Healthcare Institution Deploys DarioHealth's Full Suite, Contributing to 2025 Revenue Growth and Market Expansion

Second major healthcare employer signs with DarioHealth, accelerating growth in 2025 and reinforcing its leadership in AI-powered, clinically validated digital health solutions for chronic condition management NEW YORK, April 8, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a new employer partnership with one of the nation's most respected research and medical institutions.... Read more


Bionano Genomics Announces French Publication of an Effective Method for Analysis of Multiple Myeloma by OGM

SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a study published in The Journal of Molecular Diagnostics that describes a method for analysis of multiple myeloma (MM) by optical genome mapping (OGM). MM is one of the most common blood cancers, or hematologic malignancies, and is understood to be a difficult sample to analyze using traditional cytogenetics. Direct analysis of MM samples, by methods such as FISH or OGM,... Read more


Aspira Women's Health Appoints Three New Directors, Executes $2.0 Million Equity Purchase Agreement

New Directors Bring Extensive Commercial Healthcare Relationships to Expand Business Development Opportunities. AUSTIN, TX / ACCESS Newswire / April 8, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of three new Directors to its Board of Directors. These appointments were part of a planned Board... Read more


Sea Pharmaceuticals Announces Strategic Relationship to Advance Treatments For Patients with CNS Disorders

Sea's pre-clinical stage neurotherapeutic synthetic oral molecules act at the neurotransmitter glutamate pathway on two clinically validated targets in the CNS (central nervous system) Sea's lead molecule SPM-0404 is a potential new oral treatment in investigational new drug (IND)-enabling studies for constant bothersome tinnitus, epilepsy, and sporadic ALS (S-ALS) Pre-clinical development work by Inotiv, Inc. to support Sea filing IND application at FDA... Read more


QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook

Q1 2025 preliminary net sales rise 7% CER and adjusted diluted EPS results of at least $0.55 CER both above outlook despite challenging macro environment Full-year 2025 adjusted diluted EPS outlook raised to about $2.35 CER (prior outlook about $2.28 CER) On track to exceed 31% CER adjusted operating income margin ahead of 2028 mid-term target VENLO, Netherlands / Apr 06, 2025 / Business Wire / QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced... Read more


Telo Genomics Announces Appointment of John Farlinger to Its Board of Directors

Toronto, Ontario--(Newsfile Corp. - April 4, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that John Farlinger has joined the Company's Board of Directors. Mr. Farlinger will also serve as Chair of the Company's audit committee. Mr. Farlinger is a veteran venture and private equity... Read more


Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries

With the addition of the Pounce™ XL Thrombectomy System, indicated for use in 5.5–10 mm peripheral arteries, the fully mechanical Pounce™ Thrombectomy Platform can now remove thrombi or emboli throughout the lower and upper extremities without aspiration, thrombolysis, or capital equipment EDEN PRAIRIE, Minn. / Apr 03, 2025 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care... Read more


Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle B...

Consistent with prior studies, published results from Castle’s DECIDE study show DecisionDx-Melanoma can both accurately identify patients with less than 5% risk of sentinel lymph node (SLN) positivity, who can safely consider forgoing the sentinel lymph node biopsy (SLNB) surgical procedure, and who are also unlikely to experience disease progression1,2 As of the last follow-up, all of the patients in the third study analysis with a low-risk DecisionDx-Melanoma test... Read more


Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test

FDA approves leading solution for latent tuberculosis diagnostics, advancing global effort to fight infectious diseases WALTHAM, Mass. / Apr 02, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT™.TB test. Initially launched outside the U.S. in 2024, this powerful combination allows laboratories to improve productivity while maintaining... Read more


Quest Diagnostics Introduces HPV Specimen Self-Collection for Cervical Cancer Screening

Providers in the United States may now order the FDA-cleared HPV self-collection solution for their patients to use in their offices or other healthcare settings, with goal to reduce barriers to screening by enabling discreet self-collection Quest also plans to make self-collection option available at its 2,000 patient service centers in the United States early next month, expanding access to screening New solution follows company's launch of GTI self-collection option... Read more


Labcorp Launches First-of-its-Kind Immunoassay to Accelerate Path to Diagnosis of Alzheimer's Disease

Labcorp's pTau-217/Beta Amyloid 42 Ratio blood test meets the performance criteria to confirm amyloid pathology consistent with Alzheimer's disease BURLINGTON, N.C., April 2, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide launch of its pTau-217/Beta Amyloid 42 Ratio, a powerful new blood-based biomarker test to aid in the diagnosis of Alzheimer's disease. The new test... Read more


Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma

Two posters will share data on the significant risk stratification provided by DecisionDx-Melanoma in a real-world cohort of patients with stage IIB-IIC cutaneous melanoma (CM) to help guide adjuvant therapy, and the role of the test in prompting use of imaging surveillance in early-stage patients at high risk of metastasis to the central nervous system (CNS) FRIENDSWOOD, Texas, April 01, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving... Read more


Applied DNA Sciences Positions TR8 PGx Testing Service as Pre-Emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Anno

Company Revamps Pharmacogenomics Go-To-Market Strategy, Targets Validated PGx Assay Towards Specific Use Cases STONY BROOK, NY / ACCESS Newswire / April 1, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that Applied DNA Clinical Labs (ADCL), its wholly-owned clinical laboratory subsidiary, is repositioning its TR8™ PGx pharmacogenomics testing service to offer tailored subpanels... Read more


Government of Saskatchewan Expands Public Coverage for Dexcom Continuous Glucose Monitoring Systems

BURNABY, British Columbia / Apr 01, 2025 / Business Wire / As of today, the Government of Saskatchewan’s expanded public coverage for continuous glucose monitoring (CGM) systems comes into effect. Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, applauds this decision as a testament to the government’s commitment to improving diabetes care. The expansion, which now provides full coverage for continuous... Read more


Waters Expands Alliance iS Bio HPLC Product Line with Photodiode Array Detector to Enhance Spectral Insights for Biopharma Development & QC

News Summary Boosts out-of-the-box sensitivity by up to 80 times with MaxPeakTM Premier columns.1 Delivers over threefold improvements in day-to-day reproducibility2 and decreases carryover by up to two orders of magnitude.3 Reduces common user errors by up to 40%.4 MILFORD, Mass., April 1, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the expansion of the Alliance™ iS Bio HPLC product line with integrated photodiode array (PDA) detection,... Read more


Qiagen Launches QIAprep&amp Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts

Malaria remains a major global health threat, with more than 250 million cases and 600,000 deaths in 2024 – over 90% of them in Africa QIAprep&amp Plasmodium Kit enables streamlined detection of five malaria-causing parasites for epidemiological research and surveillance Novel QIAGEN assays support mixed-infection tracking, vaccine impact assessment and malaria control strategies in regions with limited healthcare infrastructure VENLO, Netherlands / Apr 01, 2025... Read more


Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics

FT. MYERS, Fla. / Apr 01, 2025 / Business Wire / NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO), a leading oncology testing services company, today announced that Tony Zook has officially assumed the role of Chief Executive Officer. A member of the company’s Board of Directors since 2023, Zook brings more than three decades of experience across diagnostics and biopharma, along with a proven track record of leadership in healthcare. “Tony has... Read more


Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update

Lab network revenue increased by 33% year over year, reflecting strong demand for ColoAlert® in Europe Operating loss decreased by 30% and net loss by 18%, driven by targeted cost reductions and a sharper strategic focus Strategic partnerships with industry leaders mark key progress Company highlights its early accomplishments for 2025 BERKELEY, Calif. and MAINZ, Germany, April 01, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or... Read more


Bionano Genomics Reports Fourth Quarter and Full-Year 2024 Results and Provides Revenue Outlook for 2025

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2024 and revenue outlook for 2025. “2024 has been an important year for Bionano. Despite a challenging external environment with shrinking capital budgets, financial uncertainty for our customers and difficult equity capital markets, we have continued serving our mission of transforming the way the... Read more


bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024

Increased Demand, Expanded Insurance Coverage Drive Record Growth SAN ANTONIO / Mar 31, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the year ended December 31, 2024. 2024 Highlights Record Revenue: Revenue grew approximately 270% to $9.4 million in 2024,... Read more


Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression

MALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, announced that Evernorth Health Services, a wholly owned subsidiary of The Cigna Group, has expanded its coverage of NeuroStar® Transcranial Magnetic... Read more


ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies

Enhanced strategic focus for TAEUS addresses a large, unmet global need for a cost-effective tool for monitoring liver health at the point of patient care ANN ARBOR, Mich. / Mar 31, 2025 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today announced a new strategic direction to develop and deploy its TAEUS system as a biomarker solution for the early detection and management of metabolic diseases... Read more


Twist Bioscience and Curio Genomics Collaborate to Accelerate and Streamline NGS Adoption in Agrigenomics

Collaboration to enable cost-effective end-to-end genotyping across large animal and plant populations Companies to present poster at AGBT-Ag SOUTH SAN FRANCISCO, Calif. & ANN ARBOR, Mich. / Mar 31, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Curio Genomics, a pioneer in genomics software, today announced a collaboration to accelerate... Read more


Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening

The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date MADISON, Wis. / Mar 31, 2025 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of Cologuard Plus™, the most accurate noninvasive colorectal cancer screening (CRC) test reported in studies... Read more


BioMark Diagnostics Announces the Final Closing of Oversubscribed Private Placement

Vancouver, British Columbia--(Newsfile Corp. - March 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, today announced the successful closing of its previously announced oversubscribed non-brokered private placement. The closing of the second and final tranche builds upon the momentum of the previously announced first tranche on March 26, 2025, culminating in... Read more


VolitionRx Announces Full Fiscal Year 2024 Financial Results and Business Update

Conference call to discuss financial and operational results scheduled for Monday, March 31 at 4:30 p.m. U.S. Eastern Time HENDERSON, Nevada, March 31, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the fourth quarter and full fiscal year ended December 31, 2024.  Volition management will host a conference call today, March 31 at... Read more


ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update

ANN ARBOR, Mich. / Mar 31, 2025 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the fourth quarter and full-year ended December 31, 2024, and provided a business update. Business Update ENDRA made significant progress against many of the new initiatives discussed during the Company’s August 22, 2024, conference call to advance its TAEUS Liver device along the development... Read more


Tempus AI Exhibits 4 Abstracts at the 2025 American College of Cardiology Annual Meeting

CHICAGO / Mar 29, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is scheduled to exhibit 4 abstracts at the American College of Cardiology (ACC) Annual Meeting, which convenes from March 29-31 in Chicago, Illinois. This is the first year that Tempus is presenting research, all of which highlights the application of AI to support clinicians in... Read more


Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups

New, combined validation cohort of 1,412 patients with high-risk squamous cell carcinoma (SCC) demonstrates that the addition of DecisionDx-SCC to Brigham & Women's Hospital (BWH) staging significantly refines metastatic risk prediction in patients classified as High-Risk and Very High-Risk by National Comprehensive Cancer Network (NCCN) guidelines to support improved, risk-aligned treatment pathway decisions Castle will also present new data showing DecisionDx®-Melanoma... Read more


VolitionRx Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025

Studies demonstrate how Volition's Nu.Q®H3K27Me3 biomarker, when combined with ctDNA, may improve the prognostic value for overall survival and could help inform treatment decisions in NSCLC; and how Volition's Nu.Q® H3.1, low-cost immunoassay may be utilized  for the early identification of subjects at high risk of cancer HENDERSON, Nev., March 28, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics... Read more


Neuronetics Reports Updated Fourth Quarter and Full Year 2024 Financial and Operating Results

MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) is issuing this press release to update the reporting of its financial results for the fourth quarter and full year ending December 31, 2024. Following the Company’s press release on March 4, 2025 initially issuing the Company’s fourth quarter and full year 2024 financial results (the “Initial Release”) and in connection with finalizing the... Read more


Co-Diagnostics Reports Full Year 2024 Financial Results

SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 Financial Results: Revenue of $3.9 million, which declined from $6.8 million during the prior year primarily due to higher Grant revenue in 2023. Grant revenue... Read more


Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

2,000+ Average-Risk Patient Study Seeks to Confirm Mainz Biomed’s Industry-Leading Results in the Detection of Advanced Precancerous Lesions (APL) in Independent Samples Study is on Track to Report Top-Line Results in Fourth Quarter 2025 BERKELEY, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today... Read more


Spectral Medical Announces Fourth Quarter and Fiscal 2024 Results and Provides Corporate Update

TORONTO, March 27, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2024 and provided a corporate update. The Company made significant progress throughout 2024, both clinically and operationally. Specifically, regarding its Tigris trial,... Read more


Aspira Women's Health Reports Fourth Quarter and Full Year 2024 Financial Results

Record 2024 OvaSuite revenue of $9.2 million and volume of 24,305 units sold AUSTIN, TX / ACCESS Newswire / March 27, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (Nasdaq:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the fourth quarter and year ended December 31, 2024. Select financial results are as follows: Fourth Quarter 2024 and Recent... Read more


Case Study: bioAffinity Technologies’ CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer

Case Demonstrates Benefit of Integrating CyPath® Lung into Standard of Care for Patients Under Surveillance After Treatment for Previous Lung Cancer SAN ANTONIO / Mar 26, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) today released a case study in which a positive CyPath® Lung result led to the detection of a second primary lung cancer in a high-risk patient who was previously diagnosed with stage 1A non-small cell lung cancer and underwent... Read more


Applied DNA Sciences Submits Validation Package to New York State Department of Health for H5 Bird Flu/Pan-Influenza A Laboratory-Developed Test

STONY BROOK, NY / ACCESS Newswire / March 26, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that Applied DNA Clinical Labs (ADCL), the Company's wholly-owned clinical laboratory subsidiary, has submitted a validation package to the New York State Department of Health (NYSDOH) to request approval as a laboratory-developed test (LDT) for a PCR-based assay for the detection and subtyping... Read more